Current health news includes Pfizer's lung cancer drug Lorbrena potentially hitting $1 billion in sales by 2030, U.S.
Five months after bluebird bio Inc. and Vertex Pharmaceuticals both won FDA approvals for their gene therapies to treat sickle cell disease, both companies now say their first patients have begun ...
This health news summary spotlights major developments in cancer treatments, regulatory actions on biotechnology, and the ...
Pfizer has paused its trial of a drug for a rare muscle-wasting disease after a child died suddenly. The boy, who was between two and four years old, suffered cardiac arrest after receiving the ...
A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday. The boy was enrolled in Daylight, a trial studying ...
A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7 letter (PDF) cited by nonprofit Parent Project ...
PTC Therapeutics has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC deficiency, a rare genetic ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today we ponder, how much will the advisory committee ...
Since the recombinant viral genomes are devoid of any viral genes (which are also not expressed by the infected target cell), the recombinant viral vectors can only infect a cell and are ...
When we think of smoking-related cancers, lung cancer usually comes to mind. But smoking is also a major driver for bladder cancer. Now, a new treatment has come to Philadelphia to help more ...
Pfizer and the independent external data monitoring committee said that the data is being reviewed to understand the potential cause. The patient received the investigational gene therapy ...
The US Food and Drug Administration (FDA) has approved Benlysta (belimumab) autoinjector for patients aged 5 years or older with active systemic lupus erythematosus (SLE) on standard therapy.